Clinical studies recruiting near Edwards

Studies with at least one listed site matching this location on the public registry. Each page explains the study in plain language, with locations and study-team contacts. Clinicians: generate a printable list for your patient →

Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease
Phase 2/Phase 3 · Shaw Cancer Center · Bristol-Myers Squibb · NCT07106762 Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed
Phase 3 · National Cancer Institute (NCI) · NCT06172296 Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small C
Phase 3 · NRG Oncology · NCT05624996 A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT
Phase 2 · Children's Oncology Group · NCT04322318 A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants Wit
Phase 3 · Merck Sharp & Dohme LLC · NCT06077760 Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
Phase 3 · NRG Oncology · NCT05946213 Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patient
Phase 2 · Shaw Cancer Center · NRG Oncology · NCT06532279 Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Phase 2/Phase 3 · Shaw Cancer Center · NRG Oncology · NCT05174169 Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastati
Phase 3 · Shaw Cancer Center · Alliance for Clinical Trials in Oncology · NCT06931340 TTVR STRONG Under Coverage With Evidence Development (CED) Study
Phase N/A · Edwards Lifesciences · NCT06833476 ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathol
Phase 3 · Shaw Cancer Center · Alliance for Clinical Trials in Oncology · NCT06876714 Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and S
Phase 3 · Shaw Cancer Center · Canadian Cancer Trials Group · NCT06592924 Cold and Heat Investigation to Lower Levels of Depression
NA · Vail Health Behavioral Health Innovation Center · Barry Sandler · NCT06263738 Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
Phase 2 · Alliance for Clinical Trials in Oncology · NCT06632977 Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-S
Phase 3 · National Cancer Institute (NCI) · NCT06498635 Project: Every Child for Younger Patients With Cancer
Phase N/A · Children's Oncology Group · NCT02402244 Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Inva
Phase 2 · Shaw Cancer Center · National Cancer Institute (NCI) · NCT07061964 Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectab
Phase 2 · NRG Oncology · NCT05327686 De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Eq
Phase 3 · Shaw Cancer Center · NRG Oncology · NCT04852887 Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide,
Phase 3 · Shaw Cancer Center · National Cancer Institute (NCI) · NCT06058377 Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The Co
Phase 2 · National Cancer Institute (NCI) · NCT05564377 A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Phase 3 · National Cancer Institute (NCI) · NCT05675410 Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
Phase 3 · Shaw Cancer Center · ECOG-ACRIN Cancer Research Group · NCT04423211 Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had
Phase 2/Phase 3 · SWOG Cancer Research Network · NCT06616584 Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy T
Phase 2 · Shaw Cancer Center · National Cancer Institute (NCI) · NCT06770582 Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung
Phase 3 · National Cancer Institute (NCI) · NCT04267848 Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Phase 2/Phase 3 · SWOG Cancer Research Network · NCT03851445 A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Canc
Phase 3 · Vail Health Shaw Cancer Center · Janssen Research & Development, LLC · NCT07225946 Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A L
Phase 2 · SWOG Cancer Research Network · NCT05642572 Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After
Phase 3 · Alliance for Clinical Trials in Oncology · NCT05812807

Look up another city

Look up another condition